Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Endothelin-1 and Cardio-Kidney Events among Patients with Chronic Kidney Disease, Diabetes, and Anemia
Finnian R. Mc Causland, Brian Claggett, Petr Jarolı́m, Martina M. McGrath, Emmanuel A. Burdmann, Kai-Uwe Eckardt, Andrew S. Levey, John J.V. McMurray, Giuseppe Remuzzi, Ajay Singh, Scott D. Solomon, Robert D. Toto, Marc A. Pfeffer (2025). Endothelin-1 and Cardio-Kidney Events among Patients with Chronic Kidney Disease, Diabetes, and Anemia. , DOI: https://doi.org/10.1159/000549255.
Article13 days agoMetformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease
David M. Charytan, Scott D. Solomon, Peter Ivanovich, Giuseppe Remuzzi, Mark E. Cooper, Janet B. McGill, Hans‐Henrik Parving, Patrick S. Parfrey, Ajay Singh, Emmanuel A. Burdmann, Andrew S. Levey, Kai‐Uwe Eckardt, John J.V. McMurray, Larry A. Weinrauch, Jiankang Liu, Brian Claggett, Eldrin F. Lewis, Marc A. Pfeffer (2019). Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. , 21(5), DOI: https://doi.org/10.1111/dom.13642.
Article13 days agoTreatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
Finnian R. Mc Causland, Brian Claggett, Emmanuel A. Burdmann, Glenn M. Chertow, Mark E. Cooper, Kai‐Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis, Janet B. McGill, John J.V. McMurray, Patrick S. Parfrey, Hans‐Henrik Parving, Giuseppe Remuzzi, Ajay Singh, Scott D. Solomon, Robert D. Toto, Marc A. Pfeffer (2018). Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). , 73(3), DOI: https://doi.org/10.1053/j.ajkd.2018.10.006.
Article13 days agoChange in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial
Finnian R. Mc Causland, Brian Claggett, Marc A. Pfeffer, Emmanuel A. Burdmann, Kai‐Uwe Eckardt, Andrew S. Levey, John J.V. McMurray, Giuseppe Remuzzi, Ajay Singh, Scott D. Solomon, Robert D. Toto, Patrick S. Parfrey (2017). Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. , 46(6), DOI: https://doi.org/10.1159/000485326.
Article13 days agoSupplementary Material for: Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial
Finnian R. Mc Causland, Brian Claggett, Marc A. Pfeffer, Emmanuel A. Burdmann, Kai‐Uwe Eckardt, Andrew S. Levey, McMurray J.J.V., Giuseppe Remuzzi, Ajay Singh, Scott D. Solomon, Robert D. Toto, Patrick S. ParfreySupplementary Material for: Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. , DOI: https://doi.org/10.6084/m9.figshare.5702179.
Dataset13 days ago